PROGRAM 1st German Cancer Research Congress Heidelberg 4th and 5th February 2019
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
1st German Cancer Research Congress
PROGRAM
Heidelberg
© Deutsches Krebsforschungszentrum Heidelberg
4th and 5th February 2019
CliniCian SCientiSt FellowS
FROM BEDSIDE
TO BENCH AND BACK.
TRANSLATING RESEARCH CAREERS
DKFZ
Clinician Scientist
Fellowships 2019
are you considering a career
as a clinician scientist?
the DKFZ in Heidelberg belongs to the leading
cancer research centers worldwide. team up with
a strong partner to support your translational
research ambitions!
expand your research experience and complement
your clinical training with a DKFZ Clinician Scientist
Fellowship featuring protected time for research,
comprehensive training and mentoring.
You are are a physician conducting specialized
medical training and wish to enhance your career?
apply now!
AppLICATIoN dEAdLINE: MARCH 15, 2019
more info at
www.dkfz.de/clinicianscientist
DKFZ CliniCian SCientiSt Program
Supported by the Dieter Morszeck Foundation DIETER MORSZECK
FOUNDATION
Content
Organizational Information .................................................................................................... 4
Partners .................................................................................................................................. 5
Floor Plan ............................................................................................................................... 6
General Information .............................................................................................................. 8
Scientific Program
Monday, 4th February .................................................................................. 9
Tuesday, 5th February ................................................................................... 11
Workshops
Monday, 4th February .................................................................................. 13
Tuesday, 5th February ................................................................................... 14
Poster Exhibition
Monday, 4th February .................................................................................. 15
Tuesday, 5th February ................................................................................... 31
Abstracts of the Invited Speakers .......................................................................................... 46
Abstracts of the Workshops ................................................................................................... 59
Chairs, Invited Speakers and Authors .................................................................................... 62
Heidelberg I 4th and 5th February 2019 3Organizational Information
Venue
German Cancer Research Center
Im Neuenheimer Feld 280 I 69120 Heidelberg
Congress Website
www.cancer-research-congress.com
Hosting Societies
German Cancer Research Center
www.dkfz.de
German Cancer Aid
www.krebshilfe.de
German Cancer Society
www.krebsgesellschaft.de
Congress Chairs Program Committee
Prof. Dr. Michael Baumann Prof. Dr. Peter Albers
German Cancer Research Center Prof. Dr. Michael Baumann
Prof. Dr. Martin Bornhäuser
Prof. Dr. Frederik Wenz Prof. Dr. Angelika Eggert
German Cancer Society Prof. Dr. Rainer Engers
Prof. Dr. Roland M. Schmid
Gerd Nettekoven Prof. Dr. Martin Schuler
German Cancer Aid
Professional Congress Organizer in Collaboration with
Conventus Congressmanagement & German Cancer Research Center
Marketing GmbH
Carolin Hofmann Dr. Katharina Gudd
Carl-Pulfrich-Straße 1 I 07745 Jena Im Neuenheimer Feld 280 I 69120 Heidelberg
Phone +49 3641 31 16-378 Phone +49 6221 42 2621
carolin.hofmann@conventus.de k.gudd@dkfz.de
www.conventus.de www.dkfz.de
Design/Layout
Layout krea.tif-art UG (limited liability)
Print siblog – Gesellschaft für Dialogmarketing, Fulfillment & Lettershop mbH
Circulation 700
Editorial Deadline 24th January 2019
4 1st German Cancer Research CongressPartners
National Centers for Tumor Diseases
(NCT Heidelberg and Dresden)
NATIONAL CENTER
FOR TUMOR DISEASES
PARTNER SITE DRESDEN
UNIVERSITY CANCER CENTER UCC
German Cancer Consortium
Netzwerk Onkologische Spitzenzentren
German Cancer Society
Experimental Cancer Reseach
Heidelberg I 4th and 5th February 2019 5Floor plan
1 Floor
st
Poster
Exhibition
K1/K2
Ground Floor
1st Floor
Lecture Hall
Dekade-
CornerFloor plan
Check-In
Catering
Cloakroom
ePoster Station
Live Broadcast
Conference Bags
Meetingpoint Workshops
DKH
Poster Exhibition
DKFZ
+ KID
Casino
Workshop Rooms
Main Entrance
Workshop
Rooms
State at printing.General Information
Catering
Drinks and snacks are available during the congress in the foyer of the venue. They
are included for all participants and free of charge.
Certification
The congress is accredited with 12 credits by the medical association (“Landesärz-
tekammer”) of Baden-Württemberg. To obtain your credits, please provide daily
proof of presence by scanning your name badge at the provided counter. You will
receive a certificate of attendance there.
Poster Exhibition
Poster authors will find fastening material and the program ID on the poster walls in
the poster exhibition area. Posters for the Monday exhibition must be hung by 10.30
and be removed by 18.00 on the same day.
Posters for the Tuesday exhibition must be hung by 8:00 and be removed by 16:00.
Please note that posters not removed will be treated as rubbish.
General Terms of Condition
GTC The General Terms of Condition can be found on our conference website.
Internet
A wireless network will be available within the whole building and will be free of
@
charge. Please use the following log-in data:
Username guest-0052 | Password JnOx1kuA
Parking
Please note that public parking areas are extremely limited near the conference
venue. It is recommended arriving by public transport.
Q&A with the Poster Authors
During the Q&A session, the poster authors will be available in the poster exhibition
to answer questions and get in lively discussion.
Smoking Policy
Please note that smoking is not allowed in the conference venue and within the
whole area of the German Cancer Research Center.
Media Check-In for Speakers
The media check-in for speakers ist located near the lecture hall on the ground floor.
The presentations for Monday need to be handed in by 10.15.
The presentations for Tuesday need to be handed in by 7.45.
8 1st German Cancer Research CongressScientific Program I Monday, 4th February
11.00–12.00 Opening Session
Room Lecture Hall
Chairs M. Baumann (Heidelberg), F. Wenz (Freiburg), G. Nettekoven (Bonn)
As special guests we welcome Anja Karliczek, Federal Minister of Education
and Research, as well as Theresia Bauer, Minister of Science, Research and
the Arts Baden-Württemberg.
12.00–18.00 Poster Exhibition (please see pages 15–30)
12.30–14.10 Session 1 I Prevention and Early Detection
Room Lecture Hall
Chairs M. Kiechle (Munich), P. Albers (Düsseldorf)
12.30 How many cancer cases could be avoided? The fraction of cancer
attributable to modifiable risk factors in Germany
U. Mons (Heidelberg)
12.55 Lung cancer screening by low-dose CT – recent findings from randomized
trials, and perspectives for the introduction of screening in Germany
H.-U. Kauczor, R. Kaaks (Heidelberg)
13.20 The dynamics of metastatic spread
C. Klein (Regensburg)
13.45 Hereditary breast and ovarian cancer as a paradigm for risk-adjusted
prevention and targeted therapy
R. Schmutzler (Cologne)
14.30–15.30 Q&A with the Poster Authors
During the Q&A session, the poster authors will be available in the poster
exhibition area to answer questions and get in lively discussion.
14.30–16.00 Workshops (please see page 13)
Heidelberg I 4th and 5th February 2019 9Scientific Program I Monday, 4th February
16.20–18.00 Session 2 I Personalized Oncology
Room Lecture Hall
Chairs A. Eggert (Berlin), M. Schuler (Essen)
16.20 Translating liver cancer biology – from functional target discovery to
academic drug discovery and development
L. Zender (Tübingen)
16.45 Implementing personalized lung cancer care in clinical routine
J. Wolf (Cologne)
17.10 Innovative treatment strategies in radiooncology using biomarker
stratification
M. Krause (Dresden)
17.35 From genome sequencing to translational oncology:
the Heidelberg experience
P. Lichter (Heidelberg)
18.00–21.00 Networking Dinner in the Foyer
© 135683290 l Rawpixel.com l Fotolia.com
10 1st German Cancer Research CongressScientific Program | Tuesday, 5th February
08.30–10.30 Session 3 I Imaging and Image-guided Therapy
Room Lecture Hall
Chairs H.-P. Schlemmer (Heidelberg), R. Engers (Neuss)
08.30 Small molecule inhibitors for tumor imaging and therapy
U. Haberkorn (Heidelberg)
09.00 Imaging for radiation treatment planning and monitoring in lung cancer
A. Grosu (Freiburg)
09.30 Intravital microscopy – a window into cancer resistance and immunotherapy
P. Friedl (Nijmegen/NL; Houston, TX/US)
10.00 Seeing is believing? Making sense of radiomics
A. Zwanenburg (Dresden)
08.30–16.00 Poster Exhibition (please see pages 31–46)
10.45–11.45 Q&A with the Poster Authors
During the Q&A session, the poster authors will be available in the poster
exhibition area to answer questions and get in lively discussion.
10.45–12.15 Workshops (please see page 14)
12.30–14.30 Session 4 I Tumor Immunology and Immunotherapy
Room Lecture Hall
Chairs D. Jäger (Heidelberg), M. Bornhäuser (Dresden)
12.30 Adoptive T-cell therapy
T. Blankenstein (Berlin)
12.54 Challenges in brain tumor immunotherapy
M. Platten (Mannheim)
13.18 Individualized cancer immunotherapy – beyond targeting neoantigens
U. Sahin (Mainz)
13.42 Checkpoint blockade – lessons learned in melanoma
D. Schadendorf (Essen)
Heidelberg I 4th and 5th February 2019 11Scientific Program I Tuesday, 5th February
14.06 Development of personalized treatment and novel imaging approaches for
T-cell based immunotherapies in cancer
A. Krackhardt (Essen)
14.40–16.20 Session 5 I New Target Structures in Tumor Therapy
Room Lecture Hall
Chair M. Essers (Heidelberg), M. Hallek (Cologne)
14.40 Cell plasticity in colon carcinogenesis
F. Greten (Frankfurt)
15.05 Liquid biopsy – clinical applications and current challenges
K. Pantel (Hamburg)
15.30 EMT and cell plasticity – driving force and therapeutic target in metastasis
T. Brabletz (Erlangen)
15.55 Targeting the microenvironment in myeloid malignancies
R. Schneider-Kramann (Aachen)
16.25–16.45 Concluding Remarks and Farewell
Room Lecture Hall
Chairs M. Baumann (Heidelberg), F. Wenz (Freiburg), G. Nettekoven (Bonn)
12 1st German Cancer Research CongressWorkshops I Monday, 4th February
14.30–16.00 Workshop 1 I Immunotherapy Screenings and Biomarker
Room DKFZ Main Building H2.02.073
N. Halama (Heidelberg), J. Becker (Essen)
14.30 Part 1 I Predominance of terminally differentiated T-cells among tumor
infiltrating lymphocytes impair response to PD-1/PD-L1 inhibition in Merkel
cell carcinoma
J. Becker (Essen)
15.15 Part 2 I Immunotherapy for gastrointestinal solid tumors
N. Halama (Heidelberg)
14.30–16.00 Workshop 2 I AI and Big Data in Oncology
Room A0.105/106 at ATV Building
O. Stegle (Heidelberg), J. Korbel (Heidelberg)
14.30–16.00 Workshop 3 I Preclinical Animal Tumor Models – Status Quo, Challenges,
Perspectives
Room Lecture Room 001/EG at ZMBH Building
H. Augustin (Heidelberg)
Photo / F tolia
www.conventus.de
on
© Nejr o
Success through
versatile
solutions
As a full-service PCO, we provide you with
intelligent and innovative solutions in an advisory
and implementing manner. Heidelberg I 4th and 5th February 2019 13Workshops I Tuesday, 5th February
10.45–12.15 Workshop 4 I Stem Cell Features in Cancer
Room DKFZ Main Building H2.02.073
A. Trumpp (Heidelberg)
10.45–12.15 Workshop 5 I Patient-derived Tumor Organoid Models
Room A0.105/106 at ATV Building
H. Farin (Frankfurt), T. Seidlitz (Dresden)
10.45–12.15 Workshop 6 I Organoid and Reprogramming Technologies to Model Brain
Disorders and Cancer
Room DKFZ Main Building H2.04.073
M. Mall (Heidelberg), J. Ladewig (Mannheim)
14 1st German Cancer Research CongressPoster Exhibition I Monday, 4th February
All Posters are available during the whole duration of the congress at the ePoster terminals
and at special self-study terminals.
12.00–18.00 Prevention and Early Detection
Room Casino
P001 Antibody responses to Streptococcus gallolyticus subspecies gallolyticus
proteins in a large prospective colorectal cancer cohort consortium
J. Butt (Durham, NC/US; Heidelberg), W. J. Blot (Nashville, TX/US)
L. Teras (Atlanta, GA/US), K. Visvanathan (Baltimore, MD/US)
L. Le Marchand (Honolulu, HI/US), C. Haiman (Los Angeles, CA/US)
Y. Chen (New York, NY/US), Y. Bao, H. D. Sesso (Boston, MA/US)
S. Wassertheil-Smoller, G. Ho (New York, NY/US), L. E. Tinker (Seattle, WA/US)
R. M. Peek (Nashville, TX/US), J. D. Potter (Seattle, WA/US)
T. L. Cover (Nashville, TX/US), L. Hendrix (Durham, NC/US)
L. Huang (Nashville, TX/US), T. Waterboer, M. Pawlita (Heidelberg)
M. Epplein (Durham, NC/US)
P002 Risk of invasive colorectal cancer in family members of patients with in situ
colorectal cancer
Y. Tian (Heidelberg), K. Sundquist
J. Sundquist (Shimane/JP; New York, NY/US; Malmö/SE)
H. Brenner (Heidelberg), M. Fallah, E. Kharazmi (Malmö/SE, Heidelberg)
P003 Multimarker protein signature for early detection of Colorectal Cancer
M. Bhardwaj, K. Weigl, K. Tikk, A. Benner, P. Schrotz-King
H. Brenner (Heidelberg)
P004 Risk of invasive prostate cancer for family members of in situ prostate cancer
patients – evidence from a nationwide cohort study for risk-adapted screening
X. Xu, Y. Tian (Heidelberg)
K. Sundquist, J. Sundquist (Shimane/JP; New York/US; Malmö/SE)
H. Brenner (Heidelberg), M. Fallah, E. Kharazmi (Heidelberg, Malmö/SE)
P005 Are the colorectal cancer screening methods used in Germany cost-
effective? A systematic review of European studies
C.-Y. Cheng (Heidelberg, Mannheim), T. Ran (Heidelberg)
M. Schlander (Heidelberg, Mannheim)
P006 Major non-adherence to existing surveillance guidelines within 6 years after
screening colonoscopy in Germany – prospective cohort study
M. Hoffmeister (Heidelberg), B. Holleczek (Saarbrücken), C. Stock
N. Zwink (Heidelberg), T. Stolz (Völklingen), C. Stegmaier (Saarbrücken)
H. Brenner (Heidelberg)
Heidelberg I 4th and 5th February 2019 15Poster Exhibition I Monday, 4th February
P007 Direct comparison of diagnostic performance of 9 quantitative Fecal
Immunochemical Tests (FITs) for colorectal cancer screening
A. Gies, K. Cuk, P. Schrotz-King, H. Brenner (Heidelberg)
P008 Association of aspirin and non-steroidal anti-inflammatory drugs with
colorectal cancer risk differs by molecular subtypes
E. Amitay (Heidelberg)
P009 Stage specific sensitivity of fecal immunochemical tests for detecting
colorectal cancer – systematic review and meta-analysis
T. Niedermaier, Y. Balavarca, H. Brenner (Heidelberg)
P010 Genetic risk score is associated with prevalence of advanced neoplasms in
a colorectal cancer screening population
K. Weigl, H. Thomsen, Y. Balavarca (Heidelberg), J. Hellwege
M. Shrubsole (Nashville, TX/US), H. Brenner (Heidelberg)
P011 Krebsassoziierte Fatigue – Notwendigkeit für individualisierte Konzepte zur
Prävention und Behandlung
M. Schmidt, J. Wiskemann, A. Schneeweiss, J. Debus
K. Steindorf (Heidelberg)
P012 The role of the neurotrophin receptors, TrkA/NTRK1 and TrkB/NTRK2, in
modulation of the radiation response of cancer cells
C. Hassiepen, I. Rudolf, V. Boron, A. Soni, G. Iliakis, A. Schramm (Essen)
P013 Antibodies against HPV as diagnostic and prognostic biomarker in patients
with carcinoma of unknown primary
L. Schroeder (Heidelberg), M. Pring, K. Ingarfield, S. Leary, S. Thomas
A. Waylen (Bristol/GB), M. Pawlita, T. Waterboer (Heidelberg)
A. Ness (Bristol/GB)
P014 Epidemiological risk factors for seropositivity against HPV16 oncoproteins
e6 and e7 and hpv16l1 and hpv18l1 in the uk biobank pilot study
N. Brenner (Heidelberg), A. J. Mentzer (Oxford/GB)
N. Allen (Stockport, Oxford/GB), M. Hill (Oxford/GB)
R. Almond (Stockport/GB), M. Pawlita, T. Waterboer (Heidelberg)
P015 Healthy lifestyle factors associated with lower risk of colorectal cancer
irrespective of genetic risk
P. Carr, K. Weigl, L. Jansen, V. Walter, V. Erben, J. Chang-Claude, H. Brenner
M. Hoffmeister (Heidelberg)
16 1st German Cancer Research CongressPoster Exhibition I Monday, 4th February
P016 SPAG6, NKX2-6, ITIH5 and PER1 (SNiPER) as novel methylation specific
biomarkers for liquid biopsy based early breast cancer detection
J. Mijnes, J. Tiedemann, J. Eschenbruch, J. Gasthaus (Aachen)
D. O. Bauerschlag, N. Maass (Kiel), T. Anzeneder (Munich)
P. A. Fasching (Erlangen), B. Bruno, T. Heide, N. Ortiz-Brüchle, S. von Serenyi
R. Knüchel, V. Kloten, E. Dahl (Aachen)
P017 A single pill of aspirin for enhanced early detection of colorectal neoplasms?
results of the ASTER randomized trial
K. Tikk, S. Calderazzo, A. Kopp-Schneider, D. Czock, H. Brenner (Heidelberg)
P018 Developing healthy lifestyle habits – a cancer survivorship program
M. Glausch, F. Stölzel, S. Nadja, S.,Herrmann, V. Fieber, A. Fetzer
K. Prate (Dresden), N. Ungar (Heidelberg), M. Bornhäuser (Dresden)
P019 Epstein-Barr virus serology and nasopharyngeal carcinomas in Head and
Neck 5000
J. Simon (Heidelberg), K. Ingarfield (Bristol/GB), L. Schroeder, S. Diehl
J. Werner (Heidelberg), M. Pring (Bristol/GB), M. Pawlita (Heidelberg)
A. Ness (Bristol/GB), T. Waterboer, J. Butt (Heidelberg)
P020 Tablets – Lifestyle oder auch Medium zwischen Patient und Arzt? Praktische
Erfahrungen mit der tablet-basierten Erfassung von Beeinträchtigungen und
Lebensqualität von Patienten mit Kopf-Hals-Tumoren und deren Ärzte in der
Routineversorgung
E. Peters, J. Scherf, Q. Joachim, B. Wollenberg, M. Herczeg, T. Mentler
A. Katalinic (Lübeck)
P021 Skin cancer prevention starts early in life – a sun protection preschool program
S. Nadja, F. Stölzel, M. Glausch, S. Herrmann, V. Fieber, M. Bornhäuser
E. W Breitbart (Dresden)
P022 Tryptanthrin – a novel chemopreventive against Non-melanoma skin cancer
M. S. Gopinatha Pillai (Thiruvananthapuram/IN), A. Nisthul (Kannur/IN)
S. Sundaram (Kottayam/IN), S. Chittalakkottu (Kannur/IN)
R. J. Anto (Thiruvananthapuram/IN)
P023 Determining risk of colorectal cancer and the effect of screening
colonoscopy based on genetic risk score
F. Guo, C. Chen, H. Thomsen, B. Holleczek, B. Schöttker, M. Hoffmeister
H. Brenner (Heidelberg)
Heidelberg I 4th and 5th February 2019 17Poster Exhibition I Monday, 4th February
P024 Inequalities in cancer incidence among German districts – a spatial analysis
exploring the role of behavioral and socioeconomic factors
J. Mader, K. Hernandez-Villafuerte (Heidelberg)
P025 Risk-adapted starting age of screening for first- and second-degree relatives
of breast cancer patients – evidence from a nationwide cohort study
T. Mukama, X. Xu (Heidelberg),
K. Sundquist, J. Sundquist (New York, NY/US; Lund/SE)
H. Brenner (Heidelberg), M. Fallah, E. Kharazmi (Heidelberg; Lund/SE)
P026 Bacterial whole-proteome microarrays for antigenic target identification
D. Reininger, C. Harmel, K. Hufnagel, R. Jeske, J. Butt, M. Pawlita, J. Hoheisel
T. Waterboer (Heidelberg)
P027 Telomere length, arsenic exposure and risk of basal cell carcinoma of skin
N. Kolar Srinivas (Heidelberg)
P028 Patterns of tumor progression predict small and tissue-specific tumor-
originating niches
T. Buder, A. Deutsch, B. Klink, A. Voß-Böhme (Dresden)
P029 Aberrant methylated key genes of methyl group metabolism within the
molecular etiology of urothelial carcinogenesis
S. Santourlidis, L. Erichsen (Düsseldorf)
P030 Pre- to postdiagnosis body mass index and breast cancer survival in
postmenopausal women
A. Y. Jung, S. Behrens, U. Eilber (Heidelberg), K. Thoene
D. Flesch-Janys (Hamburg), J. Chang-Claude (Heidelberg, Hamburg)
P031 Comparing the stand-alone and co-testing accuracy of cytology and HPV-
DNA tests for cervical cancer screening in Germany
L. Liang (Munich), D. Schriefer, O. Schoffer (Dresden), M. Kaiser (Mainz)
H. Ikenberg (Frankfurt), M. Blettner (Mainz), S. J. Klug (Munich)
P032 Evaluating the quality of routine Pap smears in Germany – results from a
case-control study in Germany (TeQaZ)
L. Fiengo Tanaka, S. Schülein (Munich), D. Schriefer, O. Schoffer (Dresden)
G. Schauberger, S. J. Klug (Munich)
18 1st German Cancer Research CongressPoster Exhibition I Monday, 4th February
P033 A head-to-head comparison shows differences in the cross-neutralizing
antibodies induced by bivalent and quadrivalent human papillomavirus
vaccines
F. C. Mariz, N. Bender (Heidelberg)
D. Anantharaman (Thiruvananthapuram/IN), P. Basu (Lyon/FR)
N. Bhatla (New Delhi/IN), M. Radhakrisna Pillai
P. R. Prabhu (Thiruvananthapuram/IN), R. Sankaranarayanan (Lyon/FR)
T. Eriksson (Stockholm/SE), M. Müller, K. Prager, P. Sehr, T. Waterboer
M. Pawlita (Heidelberg), M. Lehtinen (Heidelberg; Stockholm/SE)
P034 Population-based cohorts feed high-throughput laboratories for longitudinal
data acquisition – a unique approach in preventive medicine
M. Lehtinen (Heidelberg; Stockholm/SE), N. Bender (Heidelberg)
H. Artemchuk (Stockholm/SE), F. Mariz, M. Müller, P. Sehr (Heidelberg)
H.-M. Surcel (Oulu/FI), T. Waterboer (Heidelberg)
P035 Characterization of a full spectrum of cell-free RNAs in human blood plasma
using ultra-sensitive CATS approach
A. Turchinovich (Heidelberg, Mannheim), B. Burwinkel (Heidelberg)
12.00–18.00 Personalized Oncology
Room K1/K2
P036 Synthetic in vitro model of cancer stem cells in neuro oncology
C. Uhlmann, A.-C. Nickel, D. Picard, K. Koch, M. Kamp, G. Reifenberger
H.-J. Steiger, M. Sabel, M. Remke, E. Fritsche, U. Kahlert (Düsseldorf)
P037 Prospective analysis of tumor subclones in recurrent glioblastoma
V. Ullrich, S. Kebir, E. Kocakavuk, C. Dobersalske (Essen), A. Till (Bonn, Essen)
D. Trageser (Bonn), S.-T. Liffers, L. Rauschenbach, M. Dorsch (Essen)
M. Simon (Bonn), I. Cima (Essen), P. Niehusmann (Bonn), A. Rösch, U. Sure
J. T. Siveke (Essen), G. Reifenberger (Düsseldorf), H. Fröhlich (Bonn)
B. M. Grüner, M. Glas, B. Scheffler (Essen)
P038 Circulating Tumor DNA predicts Response to Treatment in BRAF and NRAS
mutant malignant Melanoma
J. Braune, L. Keller, M. Follo, E. Graf, U. Philipp, D. Pfeifer, F. Schiller
J. Duyster, F. Meiss, D. von Bubnoff, N. von Bubnoff (Freiburg)
P039 Risk-adapted colorectal cancer screening in patients with diabetes mellitus
U. Ali Khan, E. Kharazmi, M. Fallah, Y. Tian, H. Brenner (Heidelberg)
K. Sundquist, J. Sundquist (Malmö/SE)
Heidelberg I 4th and 5th February 2019 19Poster Exhibition I Monday, 4th February
P040 Molecular signature of TCRs from vaccine peptide-reactive CD4 T-cells for
monitoring the immune response in a long term responsive patient with
metastasized pancreatic ductal carcinoma during individualized
neoepitope-derived multipeptide vaccines
K. Schilbach (Tübingen)
P041 Syntaxin 18 (STX18) is a novel modulator of the radiation response in
non-small cell lung cancer (NSCLC)
C. Thumser-Henner, S. Kalmbach, A. Sak, A. Schramm, M. Schuler (Essen)
P042 Identification of novel metastasis-modulating factors in non-small-cell lung
cancer
S. Nothdurft, F. Breitenbücher (Essen), R. A. Okimoto (San Francisco, CA/US)
A. Schramm, B. M. Grüner (Essen), M. Hölzel (Bonn), J. Forster, S. Kalmbach
M. Schuler (Essen)
P043 Molecular subtypes of colorectal cancer and patient survival
E. Alwers, L. Jansen, J. Chang-Claude, H. Brenner
M. Hoffmeister (Heidelberg)
P044 Patient-derived lung cancer cell models for prediction of individual therapy
response
C. S. L. Ho, P. Stockhammer, T. Plönes, C. Aigner, M. Schuler, B. Hegedüs
A. Schramm (Essen)
P045 IMRT der pelvinen Lymphabflusswege mit simultan integriertem Boost auf
die Prostata bei Patienten mit erhöhtem Risiko für eine lymphogene
Metastasierung – Ergebnisse der PLATIN-1 Studie
S. Koerber, E. Winter, S. Katayama, V. Tarcea, I. Schlampp, J. Debus
K. Herfarth (Heidelberg)
P046 Identification of a highly lethal V3+TP53+ subset in ALK+ lung
adenocarcinoma
P. Christopoulos, M. Kirchner, S. Dietz, F. Bozorgmehr, M. Elsayed, V. Endris
J. Budczies, F. Herth, C.-P. Heussel, H. Winter, M. Eichhorn, M. Meister
T. Muley, S. Rieken (Heidelberg), T. Zemojtel (Berlin), P. Schirmacher
H. Bischoff, H. Sültmann, A. Stenzinger, M. Thomas (Heidelberg)
20 1st German Cancer Research CongressPoster Exhibition I Monday, 4th February
P047 Prediction of tumor radiation sensitivity – translation and optimization of
γH2AX foci assay for clinical use
T. Rassamegevanon (Dresden), A. Graja (Dresden, Heidelberg)
Y. Lorat (Homburg), J. Müller, S. Löck (Dresden)
M. Baumann (Heidelberg, Dresden), C. E. Rübe (Homburg)
M. Krause, C. von Neubeck (Dresden, Heidelberg)
P048 Implementation of a Molecular Tumor Board in clinical decision making at
the Medical Center University of Freiburg
N. von Bubnoff (Lübeck, Freiburg, Heidelberg), R. Höfflin
A.-L. Geißler (Freiburg), R. Fritsch (Freiburg, Heidelberg)
R. Claus (Freiburg, Augsburg), J. Wehrle, P. Metzger, M. Reiser, L. Mehmed
L. Fauth, D. H. Heiland, T. Erbes, F. Stock, A. Csanadi (Freiburg)
C. Miething (Heidelberg, Freiburg), B. Weddeling, F. Meiss, D. von Bubnoff
C. Dierks, I. Ge, S. Heeg, H. Schäfer, M. Boeker, J. Rawluk, E. Loeser
A. Tzschach, G. Kayser, S. Hettmer (Freiburg), H. Busch (Lübeck)
C. Peters, M. Werner, J. Duyster, T. Brummer, M. Börries
S. Lassmann (Freiburg, Heidelberg)
P049 Identification of familial papillary thyroid cancer predisposition genes by
whole genome sequencing
A. Srivastava, S. Giangiobbe (Heidelberg), E. Bonora (Bologna/IT)
N. Paramasivam, M. Schlesner, K. Hemminki, A. Försti
O. R. Bandapalli (Heidelberg)
P050 Using bayesian MTMK-learning to predict drug efficacy in colorectal cancer
M. Benary, P. Jähnichen, N. Blüthgen (Berlin)
P051 The target landscape of kinase inhibitors and its applications
M. Reinecke (Freising, Heidelberg, Munich), S. Heinzlmeir, S. Klaeger
M. Wilhelm, G. Médard (Freising)
B. Kuster (Freising, Heidelberg, Munich)
P052 CD33-antibody-mediated siRNA therapy targeting AML-specific oncogenes:
a proof of concept
N. Bäumer, A. Schulze, L. Terheyden, N. Appel, W. E. Berdel (Münster)
C. Müller-Tidow (Heidelberg), S. Bäumer (Münster)
Heidelberg I 4th and 5th February 2019 21Poster Exhibition I Monday, 4th February
P053 Circulating cKIT and PDGFRA DNA indicates disease activity in
Gastrointestinal Stromal Tumor (GIST)
M. Rassner (Freiburg), S. Jilg (Munich), S. Waldeck, M. Follo (Freiburg)
J. Maier (Leipzig), U. Philipp (Freiburg), V. Kehl, A. Sauter
K. Specht (Munich), C. Peschel (Freiburg, Heidelberg)
M. Schlemmer (Munich), P. Hohenberger (Mannheim), S. Bauer (Essen)
T. Lange (Weißenfels), T. Gaiser (Mannheim)
J. Duyster (Freiburg, Heidelberg), N. von Bubnoff (Heidelberg, Freiburg)
P054 Antibody-mediated RNAi-therapy controls oncogene expression in
Non-Small-Cell Lung Cancer (NSCLC) cells
A. Schulze, N. Bäumer, L. Terheyden, N. Appel, A. Gumnior
W. E. Berdel (Münster), C. Müller-Tidow (Heidelberg), S. Bäumer (Münster)
P055 Treatment strategies derived from prospective genomic and transcriptomic
sequencing in patients with advanced-stage neuroendocrine neoplasms
L. Apostolidis, S. Kreutzfeldt, M. Oleś, P. Horak, C. E. Heilig (Heidelberg)
C. Heining (Dresden), B. Hutter (Heidelberg), L. Gieldon, B. Klink (Dresden)
M. Lamping (Berlin), S. Uhrig (Heidelberg), H. Jann, U.-F. Pape (Berlin)
A. Stenzinger, E. C. Winkler (Heidelberg), B. Wiedenmann (Berlin), D. Jäger
B. Brors (Heidelberg), E. Schröck (Dresden), U. Keilholz (Berlin)
M. Pavel (Erlangen), H. Glimm (Dresden), S. Fröhling (Heidelberg)
P056 In-depth molecular characterization of Pancreatic Ductal Adenocarcinoma
based on patient-derived tumor organoids
S. Le Blanc, T. Bauer, N. Ishaque (Berlin), S. Schuth, A.-K. König
M. Volkmar, D. Hübschmann, C.-S. Leonhardt (Heidelberg)
J. Jabs (Schriesheim), M. Schenk, N. A. Giese, R. Offringa (Heidelberg)
C. Conrad (Berlin), M. Büchler, M. Schlesner (Heidelberg), R. Eils (Berlin)
O. Strobel (Heidelberg)
P057 Molecular classification of glioblastomas using a dedicated “brain tumor
panel” to uncover biomarkers for radioresistance
L. Gieldon, W. Jahn, A. Seidlitz (Heidelberg, Dresden), A. Rump
F. Zakrzewski (Dresden), K. Grützmann (Dresden, Heidelberg), M. Meinhardt
D. Aust, G. Baretton (Dresden), M. Seifert
G. Schackert (Heidelberg, Dresden)
A. von Deimling, F. Sahm (Heidelberg), D. Krex, E. Schröck
M. Krause (Dresden, Heidelberg), A. Linge (Heidelberg, Dresden)
B. Klink (Dresden, Heidelberg)
22 1st German Cancer Research CongressPoster Exhibition I Monday, 4th February
P058 Germline-testing in tumor patients – Who should be tested and what to do
with the results?
E. Schröck, A. Rump (Dresden, Heidelberg), B. Hutter (Heidelberg), A. Jahn
K. Hackmann, J. Wagner, A. Fischer (Dresden, Heidelberg)
D. William, M. Fröhlich, S. Uhrig, S. Kreutzfeldt, C. E. Heilig
D. Hübschmann (Heidelberg), B. Schlegelberger (Hannover), R. Siebert (Ulm)
E. Holinski-Feder (Munich), S. Aretz (Bonn)
N. Hoogerbrugge (Nijmegen/NL), T. Kindler (Mainz), W. Weichert
P. J. Jost (Munich), C. Brandts (Frankfurt), K. Schulze-Osthoff (Tübingen)
J. Falkenhorst (Essen), F. Klauschen (Berlin), S. Bauer (Essen)
K. Klinghammer (Berlin), G. Folprecht, M. Wermke (Dresden)
K. Spiekermann (Munich), K. Beck, S. Gröschel, B. Brors (Heidelberg)
D. Aust, G. Baretton (Dresden, Heidelberg), A. Stenzinger, L. Möhrmann
C. Heining, P. Horak, D. Richter, S. Fröhling, H. Glimm (Heidelberg), B. Klink
L. Gieldon (Dresden, Heidelberg)
P059 International consensus for DNA methylation subgroups in juvenile myelo-
monocytic leukemia and development of a common diagnostic platform
M. Schönung (Heidelberg), E. Stieglitz (San Francisco, CA/US), H. Muramatsu
N. Murakami (Nagoya/JP), M. Hartmann, M. Wiesenfarth (Heidelberg)
Y. Okuno (Nagoya/JP), A. B. Olshen (San Francisco, CA/US)
C. Plass (Heidelberg), M. L. Loh (San Francisco, CA/US), C. Niemeyer
C. Flotho (Heidelberg, Freiburg), D. B. Lipka (Magdeburg, Heidelberg)
P060 Automatischen Erfassung und Verarbeitung von
Patienteneinverständniserklärungen
P. Bronsert, M. Werner, M. Boeker (Freiburg), S. Schmid, H. Fischer
D. Kassahn (Heidelberg)
P061 Adding a proteomic dimension to INFORM/MASTER
J. Rechenberger, S. Heinzlmeir, M. Reinecke, C.-Y. Lee, J. Zecha, Y. Bian
C. Meng, M. Frejno (Freising), K.-F. Becker (Munich), S. Pfister
S. Fröhling (Heidelberg), W. Weichert (Munich), B. Kuster (Freising)
P062 Training of mutational signature-specific cutoffs for sensitive and specific
SNV and INdeL signature analysis
L. Jopp-Saile, F. Sahm, S. Fröhling, D. Hübschmann, M. Schlesner (Heidelberg)
P063 Histologische Fibrose, ein prädiktiver Faktor für postoperative Pankreas-
fisteln nach Pankreatikoduodenektomie – Ergebnisse der RECOPANC-Studie
S. Timme (Freiburg), E. Petrova (Lübeck), M. Werner (Heidelberg, Freiburg)
T. Keck (Lübeck), P. Bronsert (Heidelberg, Freiburg), U. Wellner (Lübeck)
Heidelberg I 4th and 5th February 2019 23Poster Exhibition I Monday, 4th February
P064 The influence of the bone marrow niche on drug response phenotypes of
blood cancers
S. Rabe, E. Schitter, T. Roider, P. Bruch, C. Kolb, M. Stolarczyk, J. Hüllein
J. Lu, C. von Kalle, C. Lutz, P. Dreger, C. Müller-Tidow, T. Zenz, W. Huber
S. Dietrich (Heidelberg)
P065 Clinical relevance of circulating MACC1 and S100A4 transcripts for ovarian
cancer
J. D. Kuhlmann, T. Link, D. Kobelt, P. Herrmann, Y. Vassileva, M. Kramer
K. Frank, M. Göckenjan, U. Stein, P. Wimberger (Dresden)
P066 HDACi and PLK1i synergize in MYC-amplified medulloblastoma
G. Valinciute, J. Ecker, T. Hielscher, C. Schmidt (Heidelberg)
M. Remke (Düsseldorf), G. Sigismondo, J. Krijgsveld, S. Pfister, O. Witt
T. Milde (Heidelberg)
P067 Exploring therapy response in metastatic breast cancer CTCs by single cell
analyses and patient-specific in vitro models
L. Becker, M. Fletcher, R. Würth, S. Haas, L. Velten, C. Tu, L. Michel
F. Marmé, S. Jauch, M. Becker, L. Steinmetz, M. Sprick, A. Trumpp (Heidelberg)
P068 A clear cell renal cancer metastasis model identifies novel mediators of
tumor aggressiveness and predictors of patient survival
F. Geist, T. Dolt (Heidelberg), T. Höfner (Heidelberg, Mainz), C. Klein
V. Vogel, A. Stenzinger, T. Holland-Letz, O. Kossi (Heidelberg)
W. Weichert (Munich), P. Schirmacher (Heidelberg)
S. Pahernik (Nuremberg), M. Hohenfellner, A. Trumpp, M. Sprick (Heidelberg)
P069 Characterization of detoxification mechanisms in pancreatic cancer
V. Thiel, W. Nadler, A. Kerner, B. Klaus, M. Reitberger, L. Kuhlmann, O. Kossi
V. Vogel (Heidelberg), A. Muckenhuber, W. Weichert (Munich), C. Rösli
A. Trumpp, M. Sprick (Heidelberg)
P070 Was bedeutet „personalisierte Onkologie“ für die betroffenen Patienten?
U. Goerling (Berlin), T. Pichler (Munich), A. Rohrmoser (Berlin)
E. Bierwirth, V. Heinemann, P. Heußner, P. J. Jost (Munich), U. Keilholz
M. Lamping, A. Letsch (Berlin), H. Malena, K. Riedmann, C. B. Westphalen
P. Herschbach (Munich)
P071 Optical infrared spectroscopy retrives the IDH1 genotype of fresh glioma
biopsies
O. Uckermann, R. Galli, T. Juratli, S. Michen, G. Steiner, G. Schackert
M. Kirsch (Dresden)
24 1st German Cancer Research CongressPoster Exhibition I Monday, 4th February
P072 Bayesian Methods for clinical trials in precision oncology
A. Kopp-Schneider, M. Wiesenfarth, R. Witt, O. Witt (Heidelberg)
P073 Do transposable elements play a role in the development of glioblastoma?
K. Grützmann (Dresden, Heidelberg), F. Zakrzewski (Dresden)
A. Krüger (Dresden, Heidelberg), D. Aust, E. Schröck (Dresden)
M. Schlesner, D. Jones, J. Seufert, L. Childs (Heidelberg)
M. Weller (Zurich/CH), J. Felsberg (Düsseldorf), B. Radlwimmer (Heidelberg)
G. Schackert (Dresden), J. Tonn (Munich, Heidelberg)
M. Westphal (Hamburg), H. Vatter (Bonn), A. Nordheim (Tübingen)
G. Reifenberger (Düsseldorf), B. Klink (Dresden)
P074 Establishment of a human stomach cancer biobank using organoids
T. Seidlitz, S. R. Merker, A. Rothe, D. E. Stange (Dresden)
P075 An interactive hive plot for the clinical oncological routine
J. Dieter, A. Knurr, J. Ahlbrandt, F. Ückert (Heidelberg)
P076 Creating an Effector Phenotype Map for Pancreatic Ductal Adenocarcinoma
X. Zhang, D. Saur (Munich)
P077 Genetic tumor profiles and precision oncology at the Institute of Medical
Genetics and Applied Genomics in Tübingen
F. J. Hilke, C. Roggia, S. G. Armeanu-Ebinger, A. Forschner, A. Hartkopf
I. B. Brecht, M. Schittenhelm, K. Ruhm, M. Bitzer, J. Beha
O. H. Riess (Tübingen), H.-G. Kopp (Stuttgart), C. Schroeder (Tübingen)
P078 Dual inhibition of GLUT1 and the ATR-CHK1 kinase axis displays synergistic
cytotoxicity
J. Erber, J. Steiner, J. Isensee, L. A. Lobbes, A. Toschka, F. Beleggia, F. Siedek
T. Persigehl, T. Hucho, H. C. Reinhardt (Cologne)
P079 Glutamine metabolism as a potential biomarker and target for prostate
cancer radiosensitization
A. Tyutyunnykova, O. Chen (Dresden), A. Linge (Dresden, Heidelberg)
T. Hoelscher, S. Loeck, V. Telychko, S. Richter, L. Hein (Dresden)
I.-I. Skvortsova, G. Negro, B. Aschenbrenner (Innsbruck/AT)
M. Toma (Bonn), S. Zschaeck, G. Eisenhofer, M. P. Wirth
L. A. Kunz-Schughart (Dresden), B. Tawk, C. Schwager
A. Abdollahi (Heidelberg, Dresden), G. Baretton (Dresden)
M. Krause, M. Baumann (Dresden, Heidelberg), C. Peitzsch (Dresden)
A. Dubrovska (Dresden, Heidelberg)
Heidelberg I 4th and 5th February 2019 25Poster Exhibition I Monday, 4th February
P080 Optimizing dasatinib for glioblastoma treatment
O. Alhalabi, M. Iskar, L. Puccio, B. Heßling, E. Wittmann, C. Herold-Mende
V. Goidts (Heidelberg)
P081 Deciphering and targeting oncogenic mechanisms in KRAS- and PI3K-driven
pancreatic cancer
C. Falcomatà, C. Veltkamp, X. Zhang (Heidelberg, Munich)
C. Schneeweis (Munich), M. Zukowska (Heidelberg, Munich)
R. Rad, G. Schneider (Munich), D. Saur (Heidelberg, Munich)
P082 Functional analysis of eltrombopag in a preclinical xenograft model of
Myelodysplastic Syndromes (MDS) for patient-individual placebo-controlled
substance testing
N. Schmitt, J.-C. Jann, E. Altrock, J. Flach, C. Sens-Albert, C.-A. Weis
J. Danner, S. Uhlig, A. Streuer, J. Pressler, I. Palme, V. Nowak, J. Obländer
L. Drangmeister, F. La Meir, G. Metzgeroth, A. Marx, F. Nolte
W.-K. Hofmann, D. Nowak (Mannheim)
P083 Prediction of selective genetic vulnerabilities from large-scale functional
screens in cancer cells
B. Rauscher, F. Heigwer, L. Henkel, T. Hielscher, O. Voloshanenko
M. Boutros (Heidelberg)
P084 CD4+ radiation-induced lymphocyte apoptosis (RILA) and late reaction after
radiotherapy in 252 breast cancer patients with minimum 10-year follow-up
M. R. Veldwijk (Mannheim), P. Seibold, A. Botma, I. Helmbold (Heidelberg)
E. Sperk, F. A. Giordano (Mannheim), S. Behrens (Heidelberg)
F. Wenz (Mannheim), J. Chang-Claude (Heidelberg), C. Herskind (Mannheim)
P085 Synergistic apoptosis induction in soft-tissue sarcomas by BH3-Mimetic and
proteasome inhibition
C. Hinterleitner, A. Münchow, E. Malenke, S. Bugl, S. Wirths
M. Müller (Tübingen), F. Essmann, H.-G. Kopp (Stuttgart)
P086 The Role of GSK3ß and KDM5B in the Mediation of DNA-Repair Mechanisms
in Pancreatic Cancer
G. E. Schmidt, K. Reutlinger, A. Tirilomi, L. Augustin, M. Hasselluhn
W. Kopp, H. Bohnenberger, E. Hessmann, M. Dobbelstein
V. Ellenrieder (Göttingen)
26 1st German Cancer Research CongressPoster Exhibition I Monday, 4th February
P087 Automated image-based profiling identifies compound induced phenotypes
and drug susceptibilities in patient derived organoids
J. Betge (Heidelberg, Mannheim), N. Rindtorff, B. Rauscher, J. Sauer
C. Dingert (Heidelberg), H. Gaitantzi (Mannheim), E. Valentini (Heidelberg)
S. Belle (Mannheim), T. Zhan (Mannheim, Heidelberg), K. Breitkopf-Heinlein
E. Burgermeister, M. Ebert (Mannheim), M. Boutros (Heidelberg)
12.00–18.00 Others
Room Casino
P088 Sequence-dependent cross-resistance of combined radiotherapy plus
BRAFV600E-inhibition in melanoma
B. Shannan, J. Matschke, H. Chauvistre, F. Vogel, D. Klein (Essen), F. Meier
D. Westphal (Dresden), J. Utikal (Mannheim), A. Marchetto
A. Gruenewald (Munich), D. Schadendorf, V. Jendrosek, A. Roesch (Essen)
P089 Overcoming tumor plasticity by chemically enforced phenotype
homogenization as a new therapeutic strategy in melanoma
H. Chauvistré (Essen), S. Daignault (Brisbane/AU), B. Shannan (Essen)
D. Picard (Essen, Düsseldorf), C. Krepler (Philadelphia, PA/US)
R. Ju (Brisbane/AU), F. Vogel, F. Kaschani (Essen), A. Sechi (Aachen)
O. Keminer (Hamburg), R. Varaljai (Essen, Hamburg)
S. Stehbens (Hamburg; Brisbane/AU), S. Löffek (Essen, Hamburg)
Q. Liu (Philadelphia, PA/US), S. Gul (Hamburg), A. Paschen, I. Helfrich (Essen)
M. Remke (Düsseldorf), M. Kaiser (Essen), M. Herlyn (Philadelphia, PA/US)
N. Haass (Brisbane/AU), D. Schadendorf, A. Roesch (Essen)
P090 Return to work after cancer – a multi-regional population-based study from
Germany
V. Arndt, L. Koch-Gallenkamp (Heidelberg), H. Bertram (Bochum)
A. Eberle (Bremen), B. Holleczek (Saarbrücken), R. Pritzkuleit (Lübeck)
M. Waldeyer-Sauerland (Hamburg), S. R. Zeissig (Mainz), D. Doege
M. S. Y. Thong, H. Brenner (Heidelberg)
P091 Age-specific prevalence of depression in long-term breast cancer survivors
compared to female population controls in Germany
D. Doege, M. S. Y. Thong, L. Koch-Gallenkamp, L. Jansen (Heidelberg)
H. Bertram (Bochum), A. Eberle (Bremen), B. Holleczek (Saarbrücken)
R. Pritzkuleit (Lübeck), M. Waldeyer-Sauerland (Hamburg)
A. Waldmann (Lübeck, Hamburg), S. R. Zeissig (Mainz), H. Brenner
V. Arndt (Heidelberg)
Heidelberg I 4th and 5th February 2019 27Poster Exhibition I Monday, 4th February
P092 Age at diagnosis and gender are associated with long-term deficits in
disease-specific health-related quality of life of colorectal cancer survivors:
a population-based study
M. S. Y. Thong, D. Doege, L. Koch-Gallenkamp (Heidelberg)
H. Bertram (Bochum), A. Eberle (Bremen), B. Holleczek (Saarbrücken)
M. Waldeyer-Sauerland, A. Waldmann (Hamburg), S. R. Zeissig (Mainz)
H. Brenner, V. Arndt (Heidelberg)
P093 „Still a cancer patient“ – associations of cancer identity with patient-
reported outcomes and health care use among cancer survivors
M. S. Y. Thong (Heidelberg), E.-M. Wolschon (Lübeck)
L. Koch-Gallenkamp (Heidelberg), A. Waldmann
M. Waldeyer-Sauerland (Hamburg), R. Pritzkuleit (Lübeck), H. Bertram
H. Kajüter (Bochum), A. Eberle (Bremen), B. Holleczek (Saarbrücken)
S. R. Zeissig (Mainz), H. Brenner, V. Arndt (Heidelberg)
P094 Protonenbestrahlung von Säuglingen und Kleinkindern mit Hirntumoren
D. Jazmati, M. Stickan-Verfürth, T. Steinmeier (Essen), C. Blase (Bochum)
S. Tippelt, B. Timmermann (Essen)
P095 Anti-tumourigenic effects of the iron chelator ciclopirox in HPV-positive
cancer cells
A. Herrmann, J. Braun, B. J. Kuhn, J. Krijgsveld, K. Hoppe-Seyler
F. Hoppe-Seyler (Heidelberg)
P096 Partial reprogramming of melanoma cells confers drug resistance and
increased vulnerability to calcium channel antagonists
K. Granados, L. Hüser, A. Federico (Heidelberg)
S. Sachindra (Heidelberg, Berlin), G. Wolff, D. Novak, V. Umansky
J. Utikal (Heidelberg)
P097 Single cell cell-fate choices in response to Cisplatin
A. Granada (Berlin), J. Stewart-Ornstein (Pittsburgh, PA/US)
G. Lahav (Boston, MA/US)
P098 Repression of human papillomavirus oncogene expression under hypoxia is
mediated by PI3K/mTORC2/AKT signaling
F. Bossler, B. J. Kuhn, J. Krijgsveld, K. Hoppe-Seyler
F. Hoppe-Seyler (Heidelberg)
28 1st German Cancer Research CongressPoster Exhibition I Monday, 4th February
P099 ADAM9 contributes to vascular invasion in pancreatic ductal adeno-carcinoma
V. O. Oria, P. Lopatta, T. Schmitz (Freiburg), B.-T. Preca (Basel/CH)
A. Nyström (Freiburg), C. Conrad (Münster, Marburg)
J. W. Bartsch (Marburg), B. Kulemann, J. Höppner (Freiburg)
J. Maurer (Aachen), P. Bronsert, O. Schilling (Heidelberg, Freiburg)
P100 Retrospective study of paclitaxel in advanced therapy lines in the treatment
of SCLC
D. von Eiff, F. Bozorgmehr, P. Christopoulos, I. Chung, D. Bernhardt
S. Rieken, S. Liersch, S. Kobinger, M. Thomas, M. Steins (Heidelberg)
P101 Cellular plasticity within the prostate cancer stem cell population upon
irradiation
F. Schwarz (Dresden), A. Wursthorn, A. Nowrouzi, I. Kurth
M. Baumann (Heidelberg), M. Krause, A. Dubrovska, C. Peitzsch (Dresden)
P102 Measuring health-related quality of life for economic analysis and health
technology assessment (HTA) – Why we should exercise caution when
using generic Multi-Attribute Utility (MAU) measurement instruments?
D. Hernandez, M. Schlander, O. Schwarz (Heidelberg), J. Richardson
M. Khan (Melbourne/AU)
P103 The economic burden of cancer in Germany
K. Hernandez-Villafuerte, M. Schlander, C. Thielscher (Heidelberg)
P104 DNA methylation changes define hematopoietic lineage commitment
S. Kraemer, S. Staeble, J. Langstein, R. Bogeska, D. Weichenhan
D. Huebschmann, J. Knoch, O. Muecke, M. Helf (Heidelberg)
M. Czeh (Oxford/GB; Münster), J. Graesel (Heidelberg)
F. Rosenbauer (Münster), R. Eils (Berlin), C. Plass, M. Schlesner
M. D. Milsom, D. B. Lipka (Heidelberg)
P105 Therapeutic effects of combined radiotherapy and DNA dependent protein
kinase inhibitor
N. Ebert (Heidelberg, Dresden), C. von Neubeck (Dresden, Heidelberg)
P. Naas, A. Schulz (Dresden), S. Löck (Heidelberg, Dresden)
A. Zimmermann (Darmstadt), M. Krause, M. Baumann (Heidelberg, Dresden)
P106 Decreased CYP3A activity in palliative cancer patients
M. Geist, H. Bardenheuer, J. Burhenne, G. Mikus (Heidelberg)
Heidelberg I 4th and 5th February 2019 29Poster Exhibition I Monday, 4th February
P107 Transcriptomic landscape of human epithelial and stromal cells isolated from
cancer and normal pancreatic tissue dissects cross-talks and deregulated
signaling happening at cell-type level
E. Espinet, Z. Gu, C. D. Imbusch, V. Vogel, N. A. Giese, T. Hackert
O. Strobel (Heidelberg), W. Weichert (Munich), M. Sprick
A. Trumpp (Heidelberg)
P108 Physical activity and long-term quality of life among colorectal cancer
survivors – a population-based prospective study
R. E. Eyl, L. Koch-Gallenkamp, L. Jansen, V. Walter, P. Carr, M. Hoffmeister
J. Chang-Claude, H. Brenner, V. Arndt (Heidelberg)
P109 Circulating osteoprotegerin and TRAIL and breast cancer survival and
recurrence in the MARIE breast cancer cohort
A. Y. Jung, C. Le Cornet (Heidelberg), D. Sarink (Heidelberg; Honolulu, HI/US)
S. Behrens, T. Johnson (Heidelberg), T. Maurer, N. Obi (Hamburg)
J. Chang-Claude (Heidelberg, Hamburg), R. T. Fortner (Heidelberg)
P 143 The JAK inhibitor Ruxolitinib offers an effective treatment strategy for
peripheral T-cell Lymphomas
S. Madan Mohan Gambheer, A. Jäger (Freiburg)
30 1st German Cancer Research CongressPoster Exhibition I Tuesday, 5th February
All Posters are available during the whole duration of the congress at the ePoster terminals
and at special self-study terminals.
08.30–16.00 Imaging and Image-guided Therapy
Room Casino
P 111 Etablierung einer dezentralen Prüfarzneimittel-Herstellung in mehreren
Radiopharmazien am Beispiel der prospektiven klinischen DKTK-Multicenter-
Studie „Ga-68-PSMA-11 in high-risk prostate cancer“
C. Zippel, O. C. Neels, U. Hennrich (Heidelberg), G. Kabuss (Radeberg)
S. D. Müller, A. Reil-Held, F. L. Giesel, K. Kopka (Heidelberg)
P 112 Innate immune cell tracking in the glioma microenvironment by correlated
magnetic resonance imaging and mutiphoton microscopy (MR-MPM)
K. Karimian-Jazi, P. Münch, A. Alexander, M. Piechotta, M. Karreman, W. Wick
M. Bendszus, F. Winkler (Heidelberg), M. Platten (Heidelberg, Mannheim)
M. Breckwoldt (Heidelberg)
P 113 Histogram and texture features in baseline diffusion-weighted MRI predict
patient survival, subtype and therapy response in pancreatic ductal
adenocarcinoma
G. Kaissis, S. Ziegelmayer, F. Lohöfer, I. Heid (Munich), J. T. Siveke (Essen)
D. Ankerst, H. Friess, H. Algül, R. Schmid, E. J. Rummeny, W. Weichert
R. Braren (Munich)
P 114 Borderline-resectable pancreatic adenocarcinoma – contour irregularity of
the venous confluence in pre-operative computed tomography predicts
histopathological infiltration
G. Kaissis, F. Lohöfer, S. Ziegelmayer, J. Danner, C. Jäger, R. Schirren, D. Ankerst
G. O. Ceyhan, H. Friess, E. J. Rummeny, W. Weichert, R. Braren (Munich)
P 115 Carbon Ion reirradiation for recurrent head-and-neck cancer – a single-
institutional experience
T. Held, P. Windisch, S. Akbaba, K. Lang, D. Bernhardt, P. Plinkert, K. Freier
S. Kargus, S. Rieken, K. Herfarth, J. Debus, S. Adeberg (Heidelberg)
P 116 Intention to treat-Analyse von 68Ga-PSMA- und 11C-choline PET/CT versus CT
bei Prostatakarzinomrezidiven nach Operation
A.-C. Müller, S.-C. Olthof, C. Pfannenberg, D. Wegener, J. Marzec, J. Bedke
A. Stenzl, C. la Fougère, K. Nikolaou, D. Zips, J. Schwenck (Tübingen)
Heidelberg I 4th and 5th February 2019 31Poster Exhibition I Tuesday, 5th February
P 117 MR-guided radiotherapy (MRgRT) der Prostataloge – erste Erfahrungen an
einem Hoch-Feld-MR-Linac
A.-C. Müller (Tübingen, Heidelberg), D. Wegener, S. Böke (Tübingen)
D. Mönnich (Tübingen, Heidelberg), C. Marks, A. Stolte, O. Dohm (Tübingen)
D. Thorwarth (Heidelberg, Tübingen), C. Gani (Tübingen)
D. Zips (Tübingen, Heidelberg), M. Nachbar (Tübingen)
P 118 BRAF-Mutationsanalyse zur initialen Risikostratifizierung beim papillären
Schilddrüsenkarzinom der Hochrisikogruppe
I. Binse, J. Pokladek, M. Weber, S. Theurer, W. Jentzen, L. Umutlu
K. Herrmann, R. Görges (Essen)
P 119 Dual-energy computed tomography for improved proton therapy treatment
planning
N. Peters, P. Wohlfahrt (Dresden), C. Möhler, S. Greilich (Heidelberg)
C. Richter (Dresden)
P 120 Ultra-early response capturing in the treatment of non-squamous NSCLC
using diffusion-weighted MRI – a prospective multicenter study
G. Heussel, N. V. Batora, C. F. Silva, M. A. Schneider, I. Chung, P. Flechsig
J. Krisam, C. Wiedemann, O. Sedlaczek, I. Fellhauer, H.-U. Kauczor
M. Thomas (Heidelberg), H. Golpon, J. Vogel-Claussen (Hannover), A. Tufman
J. Dinkel (Munich), A. Guenther (Giessen), S. Janciauskiene (Hannover)
H. Sültmann, M. Meister, C. P. Heussel, F. Bozorgmehr (Heidelberg)
P 121 Bildmerkmale aus PSMA PET Bildern zur nicht-invasiven Tumordetektion und
Charakterisierung des Gleason Scores in Patienten mit primärem
Prostatakarzinom
C. Zamboglou, M. Carles, T. Fechter, S. Kiefer, P. Bronsert, J. Ruf
T. F. Fassbender, K. Reichel, M. Werner, C. A. Jilg, D. Baltas, M. Mix
A. Grosu (Freiburg)
P 122 Machbarkeitsstudie zur MRT-integrierten protonentherapie – Bildqualität,
Strahlablenkung und Sekundärelektronen
S. Schellhammer, S. Gantz, A. Lühr, J. Pawelke, L. Karsch (Dresden), J. Smeets
S. Quets (Louvain-la-Neuve/BE), L. N. Burigo (Heidelberg)
B. Oborn (Wollongong/AU), M. Bussmann, A. Hoffmann (Dresden)
P 123 Deep learning for the diagnostics of cancer tissue in pathology
F. Zakrzewski, W. de Back, M. Weigert, T. Wenke, S. Zeugner, S. Schmell
R. Mantey, K. Friedrich, I. Röder, D. E. Aust, P. Hönscheid, G. Baretton (Dresden)
32 1st German Cancer Research CongressPoster Exhibition I Tuesday, 5th February
P 124 Online high-field MR-guided Radiotherapy – initial experience in Tübingen
C. Gani (Heidelberg, Tübingen), M. Nachbar, D. Mönnich (Tübingen)
K. Nikolaou (Tübingen, Heidelberg), S. Gatidis, U. Grosse, F. Schick
N. Weidner, A.-C. Müller, S. Böke (Tübingen), D. Thorwarth
D. Zips (Heidelberg, Tübingen)
P 125 Analyse einer MR-geführten Bestrahlung mit unterschiedlichen online
Adaptationsalgorithmen in einem Hoch-Feld-MR-Linac
M. Nachbar, D. Mönnich, C. Marks, A. Stolte, O. Dohm (Tübingen)
A.-C. Müller, D. Thorwarth, D. Zips (Tübingen, Heidelberg)
C. Gani (Heidelberg, Tübingen), S. Böke (Tübingen, Heidelberg)
P 126 Nicht-invasiv bestimmte Hypoxie und funktionelle MRT in Kopf-Hals-Tumor
Xenografts während fraktionierter Bestrahlung
S. Böke (Tübingen, Heidelberg), P. Mena Romano, S. Leibfarth
R. M. Winter, E. C. Sezgin, M. Krueger, G. Bowden, J. Cotton (Tübingen)
B. Pichler, D. Zips, D. Thorwarth (Tübingen, Heidelberg)
P 127 A comprehensive analysis pipeline for MALDI imaging data in Galaxy
M. C. Föll, L. Moritz (Freiburg), T. Wollmann (Heidelberg), M. Stillger
M. Werner, P. Bronsert (Freiburg), K. Rohr (Heidelberg), B. Grüning
O. Schilling (Freiburg)
P 128 Measure where protons stop in the patient – verification of proton therapy
by means of prompt gamma rays
C. Khamfongkhruea, L. Nenoff, M. Priegnitz, S. Barczyk, J. Berthold (Dresden)
L. Hotoiu, G. Janssens, J. Petzoldt, J. Smeets (Louvain-la-Neuve/BE)
W. Enghardt (Heidelberg, Dresden), G. Pausch (Dresden)
C. Richter (Dresden, Heidelberg)
P 129 Investigating orthotopic tumour growth of non-small cell lung carcinoma
Models – impact of transplantation technique and evaluation of preclinical
imaging modalities
R. Aktar, A. Dietrich (Dresden, Heidelberg), F. Tillner (Dresden)
S. Kotb, S. Löck (Dresden, Heidelberg), H. Willers (Boston, MA/US)
M. Baumann, M. Krause, R. Bütof (Dresden, Heidelberg)
P 130 Investigation of the availablity of sigma-1 receptors in orthotopic human
glioblastoma-bearing mice with positron emission tomography (PET) using
(S)-(−)-[18F]fluspidine
M. Toussaint, M. Kranz, W. Deuther-Conrad, M. Patt, O. Sabri, P. Brust (Leipzig)
Heidelberg I 4th and 5th February 2019 33Poster Exhibition I Tuesday, 5th February
P 131 Diffusion weighted imaging at 7T for subgroup stratification of murine
endogenous Pancreatic Ductal Adenocarcinoma
I. Heid, G. Topping, F. Englert, K. Steiger, E. J. Rummeny, M. Schwaiger
D. Karampinos, F. Schilling, R. Braren (Munich)
P 132 Harmonizing MR-Diffusion imaging using phantom calibration:
a multi-center evaluation of the German Cancer Consortium Joint Imaging
Platform (DKTK-JIP) Initiative
J. Kleesiek, M. Bach, T. Kuder, M. Nolden, K. Maier-Hein (Heidelberg)
A. Radbruch (Essen, Heidelberg), H.-P. Schlemmer (Heidelberg)
DKTK Joint Imaging Platform
P 133 Robust intensity-modulated proton therapy with simultaneous integrated
boost reduces the low-dose to surrounding tissues in pancreatic cancer
patients
S. Stefanowicz (Dresden), S. Zschaeck (Berlin)
E. G. C. Troost (Heidelberg, Dresden)
P 134 Parametric sensitivity analysis of a mathematical model for hypoxia-PET
radiotracer dynamics
I. Paredes Cisneros (Heidelberg), A. Gago-Arias, I. Espinoza
P. Caprile (Santiago/CL), D. Nolte (Santiago/CL; Groningen/NL)
C. P. Karger (Heidelberg)
P 135 The Joint Imaging Platform (JIP) of the German Cancer Consortium (DKTK):
a distributed infrastructure for image analysis and machine learning in
multicenter oncological studies
M. Nolden, J. Kleesiek, J. Scherer, J. Metzger, K. Kades (Heidelberg)
A. Radbruch (Heidelberg, Essen), H.-P. Schlemmer, K. Maier-Hein (Heidelberg)
08.30–16.00 Tumor Immunology and Immunotherapy
Room Casino
P 136 Identification of superior combinatorial PDA therapies involving cytostatic
agents and immunostimulatory antibodies in a clinically relevant mouse
model
D. Baumann, T. Hägele, J. Mochayedi, S. Blobner, J. H. Noll, C. Vent, J. Drebant
M. Volkmar, R. Offringa (Heidelberg)
34 1st German Cancer Research CongressPoster Exhibition I Tuesday, 5th February
P 137 Bulk and single-cell T-cell receptor and transcriptome profiling reveals
significant phenotypic, spatial and temporal heterogeneity in the tumor-
infiltrating lymphocyte repertoire of pancreatic cancer and melanoma
patients
I. Poschke, C. L. Tan, I. Heras Murillo, K. Lindner, A. Rodriguez Ehrenfried
M. W. Büchler (Heidelberg), U. Sahin (Mainz), J. Hassel, O. Strobel
R. Offringa (Heidelberg), M. Floßdorf (Munich), L. Appel
K. König (Heidelberg)
P 138 Sensitive and specific identification of mutanome-encoded T-cell epitopes in
PDAC on the basis of Xenograft NGS data using a Hybrid Reference Genome
M. Volkmar (Heidelberg), D. Hoser (Berlin), C. Lauenstein, J. Rebmann
A. Hotz-Wagenblatt, J. Rieger, I. Poschke, S. Blobner, C. Lehmann, M. Sprick
A. Trumpp, M. W. Büchler, O. Strobel (Heidelberg), G. Willimsky (Berlin)
R. Offringa (Heidelberg)
P 139 Targeted delivery of a toll-like receptor 3 agonist for adjuvant tumor therapy
of glioblastoma multiforme
A. Hagstotz, S. Michen, G. Schackert, A. Temme (Dresden)
P 140 Expansion of primary NK cells for targeting EGFR-positive, KIR/KIR-ligand-
matched glioblastoma and autologous melanoma cells using cetuximab
S. Michen (Dresden), N. Pieper, A. Paschen (Essen), J. Frosch (Dresden)
G. Schackert, A. Temme (Dresden)
P 141 Combined HLA class I and HLA class II genotype alterations in melanoma from
patients with primary and acquired resistance to immune checkpoint blockade
F. Zhao, M. Schwamborn, B. Thier, P. Crivello, A. Heinold, T. Meuer (Essen)
V. Lennerz (Mainz), A. Sucker, K. Griewank, P. A. Horn, S. Ugurel (Essen)
T. Wölfel (Mainz), K. Fleischhauer, D. Schadendorf, A. Paschen (Essen)
P 142 Durvalumab in frail and elder patients with stage four NSCLC – the DURATION
trial
J. Kuon, M. A. Schneider, J. Krisam, F. Lasitschka (Heidelberg)
M. Faehling (Esslingen), M. Ulmer (Ludwigsburg), M. Kimmich (Gerlingen)
W. Schuette (Halle a. d. Saale), M. Serke (Hemer), P. Schuett (Gütersloh)
W. Gleiber (Frankfurt), N. Moosmann (Regensburg)
L. Fischer von Weikersthal (Amberg), C. Meyer zum Büschenfelde (Karlsruhe)
C. Kropf-Sanchen (Ulm), H. Bernhard (Darmstadt), M. Boesche (Greifswald)
C. Denzlinger (Stuttgart), J. R. Fischer (Loewenstein), V. van Laak (Berlin)
C. Maintz (Würselen), M. Wermke (Dresden), M. Thomas (Heidelberg)
Heidelberg I 4th and 5th February 2019 35You can also read
